Videos

A discussion about the Association for Professionals in Infection Control and Epidemiology with CEO Devin Jopp.

Seqirus is seeking reactogenicity and immunogenicity outcomes between its influenza vaccines and available mRNA vaccines for COVID-19.

Plus: how could the COVID-19 testing market boom improve public flu awareness?

COVID-19 response restrained flu outbreaks last year. An expert explains his concern that won't be enough this winter.

An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.

An interview with a study author on unique associations between county infrastructures and COVID-19 fatality rates.

A discussion surrounding Novavax’s NVX-CoV2373 with Lisa Dunkle, MD.

With the company reporting its data today and it applying for authorization with regulatory bodies internationally, and later this year with the US Food and Drug Administration (FDA), what does the prospect of this new vaccine mean to people in the US and internationally?

Cartesian Therapeutics has created its therapy, Descartes-30, the first RNA cell therapy for acute respiratory distress syndrome (ARDS), and the company is now recruiting for a clinical trial.

A Q&A surrounding the two technologies with investigators from the Wistar Institute.

With the US Centers for Disease Control and Prevention's recent change to mask guidance for vaccinated people, some confusion ensued and left state governments and businesses scrambling to react to the update.

During the COVID-19 surge last year, the federal government stopped the required reporting on healthcare-associated infections (HAI) thus leaving an absence of data and important information on HAI. One study examined the effect the initial pandemic surge had on Clostridioides Difficile infection (CDI) in one hospital.

Do the very freedoms Americans enjoy allow us to make less than optimal choices? And will it prevent us from doing what medical science says is best if needed again?

A discussion on issues surrounding the treatment of HIV with Melissa Badowski, PharmD, MPH.

A study looked at hospital admissions of Medicare patients and saw a large percentage of recurrent Clostridioides difficile infections (rCDI) as the primary diagnosis.

A diagnostic analyzer was studied looking at 3 biomarkers to predict the level of COVID-19, and could potentially serve as a risk stratification tool.

As the HIV population ages, a variety of health challenges may arise that typically happen in populations without chronic conditions.

This is our inaugural segment for our new video series, 1 Big Question, where we ask the medical community a question about a significant infectious disease topic and get feedback from them.

A cardiology expert discusses the unique and currently investigated relationship between COVID-19, adenovirus vaccines, and thrombotic events.

The ATLAS 2M study results showed non-inferiority in 2-month dosing compared to 1-month dosing for the cabotegravir and rilpivirine long-acting injectable.

An interventional cardiologist discusses the observed cases of cerebral venous thrombosis in women administered the Johnson & Johnson COVID-19 vaccine.

Carlos del Rio, MD, discusses the United States' pandemic situation in assessing the blood clot events observed in 6 Johnson & Johnson vaccine recipients.

Jason Gallagher, PharmD, adds context behind the FDA and CDC's decision to pause and review blood clotting events in 6 women given the company's COVID-19 vaccine.

A recent study looked at the racial disparities amongst people living with HIV and COVID-19 positivity rates.

An expert stresses the need to consider individuals' worry over information—and even their history with systemic biases.

Vaccine access and new cases are both increasing. An expert discusses earning trust in at-risk communities.

Long-acting injectables for latent and active tuberculous (TB) might be a treatment option in the future and could open up the door to possibly bundling HIV and TB care together.

To mark World TB Day, a pair of experts break down the currently defined regimens for latent and active tuberculosis—and what may still come.

The small country's emphasis on accessible testing provided more up-to-date tracking, and opportunity for research into reinfection risk.

An interview on perspectives learned from a nationwide PCR test database assessment.